• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由HIV-1高变中和决定簇引发的广泛中和抗体。

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

作者信息

Javaherian K, Langlois A J, LaRosa G J, Profy A T, Bolognesi D P, Herlihy W C, Putney S D, Matthews T J

机构信息

Department of Surgery, Duke University Medical School, Durham, NC 27710.

出版信息

Science. 1990 Dec 14;250(4987):1590-3. doi: 10.1126/science.1703322.

DOI:10.1126/science.1703322
PMID:1703322
Abstract

The principal neutralizing determinant (PND) of human immunodeficiency virus (HIV)-1 resides within the V3 loop of the envelope protein. Antibodies elicited by peptides of this region were able to neutralize diverse isolates. Serum from one of three animals immunized with the human T cell lymphoma virus (HTLV)-IIIMN PND peptide, RP142, neutralized MN and the sequence-divergent HTLV-IIIB isolate. Serum from one of three animals immunized with a 13-amino acid IIIB PND peptide (RP337) also neutralized both of these isolates. Characterization of these sera revealed that the cross-neutralizing antibodies bound the amino acid sequence GlyProGlyArgAlaPhe (GPGRAF) that is present in both isolates. This sequence is frequently found in the PNDs analyzed in randomly selected HIV-1 isolates. Sera from two rabbits immunized with a peptide containing only the GPGRAF residues neutralized divergent isolates, including IIIB and MN.

摘要

人类免疫缺陷病毒1型(HIV-1)的主要中和决定簇(PND)位于包膜蛋白的V3环内。该区域肽段引发的抗体能够中和多种分离株。用人类T细胞淋巴瘤病毒(HTLV)-IIIMN PND肽RP142免疫的三只动物中,有一只动物的血清能中和MN以及序列不同的HTLV-IIIB分离株。用一种13个氨基酸的IIIB PND肽(RP337)免疫的三只动物中,有一只动物的血清也能中和这两种分离株。对这些血清的特性分析表明,交叉中和抗体结合了两种分离株中都存在的氨基酸序列甘氨酸-脯氨酸-甘氨酸-精氨酸-丙氨酸-苯丙氨酸(GPGRAF)。在随机选择的HIV-1分离株中分析的PND中经常发现该序列。用仅含GPGRAF残基的肽免疫的两只兔子的血清能中和包括IIIB和MN在内的不同分离株。

相似文献

1
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.由HIV-1高变中和决定簇引发的广泛中和抗体。
Science. 1990 Dec 14;250(4987):1590-3. doi: 10.1126/science.1703322.
2
Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.HIV-1阳性个体以及经实验免疫的灵长类动物和啮齿动物的抗体与gp120第三可变区(V3)的序列不同区域结合。
Int Immunol. 1992 Feb;4(2):283-94. doi: 10.1093/intimm/4.2.283.
3
Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.用来自gp120第三可变区的合成肽产生的1型人类免疫缺陷病毒特异性单克隆抗体和组特异性多克隆中和抗体。
J Virol. 1992 Mar;66(3):1823-31. doi: 10.1128/JVI.66.3.1823-1831.1992.
4
Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
AIDS. 1994 Aug;8(8):1089-96. doi: 10.1097/00002030-199408000-00008.
5
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.具有保守结构的1型人类免疫缺陷病毒中和表位在实验感染的黑猩猩中引发早期型特异性抗体。
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82. doi: 10.1073/pnas.85.12.4478.
6
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.猴免疫缺陷病毒的主要中和决定簇与1型人类免疫缺陷病毒的不同。
Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418-22. doi: 10.1073/pnas.89.4.1418.
7
Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1).
Vaccine. 1997 Aug;15(11):1200-8. doi: 10.1016/s0264-410x(97)00012-1.
8
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.由包膜糖蛋白120 T辅助细胞位点和B细胞中和表位组成的多价人类免疫缺陷病毒合成免疫原。
J Immunol. 1989 May 15;142(10):3612-9.
9
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.可变区3(V3)突变决定了一种与广泛交叉反应的原发性病毒中和抗体反应相关的人类免疫缺陷病毒1型包膜的整体中和表型和不依赖CD4的感染性。
J Virol. 2002 Jan;76(2):644-55. doi: 10.1128/jvi.76.2.644-655.2002.
10
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.用人免疫缺陷病毒env编码的合成肽抗体进行型特异性中和
Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6. doi: 10.1073/pnas.85.6.1932.

引用本文的文献

1
The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research.bnAb产生机制及其在可变病毒广谱疫苗中的应用:来自HIV-1广泛中和研究的启示
Vaccines (Basel). 2023 Jun 25;11(7):1143. doi: 10.3390/vaccines11071143.
2
Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future.SARS-CoV-2 和 HIV 表面包膜糖蛋白的趋同进化动力学受宿主细胞表面受体和脂筏驱动:对未来的启示。
Int J Mol Sci. 2023 Jan 18;24(3):1923. doi: 10.3390/ijms24031923.
3
Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
利用广谱中和抗体作为人类免疫缺陷病毒的预防和治疗应用。
Front Immunol. 2021 Jul 20;12:697683. doi: 10.3389/fimmu.2021.697683. eCollection 2021.
4
Strategies for inducing effective neutralizing antibody responses against HIV-1.诱导针对 HIV-1 的有效中和抗体反应的策略。
Expert Rev Vaccines. 2019 Nov;18(11):1127-1143. doi: 10.1080/14760584.2019.1690458. Epub 2019 Dec 2.
5
Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.建立疫苗研发的保护相关性:呼吸道合胞病毒疫苗领域的考量
Viral Immunol. 2018 Mar;31(2):195-203. doi: 10.1089/vim.2017.0147. Epub 2018 Jan 16.
6
Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.合成三组分 HIV-1 V3 糖肽免疫原诱导糖依赖性抗体反应。
Cell Chem Biol. 2017 Dec 21;24(12):1513-1522.e4. doi: 10.1016/j.chembiol.2017.09.005. Epub 2017 Oct 26.
7
Progress toward active or passive HIV-1 vaccination.HIV-1主动或被动疫苗接种的进展。
J Exp Med. 2017 Jan;214(1):3-16. doi: 10.1084/jem.20161765. Epub 2016 Dec 21.
8
Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.使用V3模拟表位肽在恒河猴中诱导中和抗体
Vaccine. 2016 May 23;34(24):2713-21. doi: 10.1016/j.vaccine.2016.04.027. Epub 2016 Apr 19.
9
HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.HIV包膜三聚体特异性免疫反应受不同佐剂配方和异源初免-加强免疫的影响。
PLoS One. 2016 Jan 4;11(1):e0145637. doi: 10.1371/journal.pone.0145637. eCollection 2016.
10
Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.涉及HIV-1包膜V3区的结构/功能研究揭示了影响中和敏感性的多种因素。
J Virol. 2015 Oct 21;90(2):636-49. doi: 10.1128/JVI.01645-15. Print 2016 Jan 15.